Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) Revenue (2016 - 2026)

Dexcom has reported Revenue over the past 17 years, most recently at $1.2 billion for Q1 2026.

  • Quarterly Revenue rose 15.05% to $1.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.8 billion through Mar 2026, up 16.15% year-over-year, with the annual reading at $4.7 billion for FY2025, 15.6% up from the prior year.
  • Revenue was $1.2 billion for Q1 2026 at Dexcom, down from $1.3 billion in the prior quarter.
  • Over five years, Revenue peaked at $1.3 billion in Q4 2025 and troughed at $628.8 million in Q1 2022.
  • The 5-year median for Revenue is $994.2 million (2024), against an average of $965.8 million.
  • Year-over-year, Revenue increased 26.9% in 2023 and then increased 1.97% in 2024.
  • A 5-year view of Revenue shows it stood at $815.2 million in 2022, then increased by 26.9% to $1.0 billion in 2023, then rose by 7.64% to $1.1 billion in 2024, then rose by 13.12% to $1.3 billion in 2025, then dropped by 5.37% to $1.2 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Revenue are $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025).